Lv11
35 积分 2021-07-28 加入
Daratumumab: A review of current indications and future directions
1小时前
已完结
The multiple myeloma drug market
22天前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
30天前
已完结
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program
30天前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
1个月前
已完结
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
1个月前
已完结
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
1个月前
已完结
A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
1个月前
已关闭
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
1个月前
已完结
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity
2个月前
已完结
皖公网安备34019202002308
